Summary of the Medical Aesthetics and Cosmetics Industry Conference Call Industry Overview - The medical aesthetics industry in China has a significantly lower penetration rate compared to the US and South Korea, indicating substantial growth potential. The current penetration rate is approximately 2 per 1,000 people, while the US and South Korea have rates of 5‰ and 8‰ respectively, suggesting a large market opportunity for growth [2][3][4] - The consumer repurchase rate for medical aesthetics is high, with stable demand for light medical aesthetics services, which provides a solid foundation for industry development [2][3] Market Dynamics - The medical aesthetics industry is divided into two main segments: medical aesthetics and cosmetics. The medical aesthetics segment remains robust post-pandemic, with a focus on product and material development [3][4] - The upstream raw material sector has high gross margins, with companies like Aimeike achieving margins of 85%-90%. The typical markup at the consumer level is over three times the factory price, ensuring profitability for institutions and sales personnel [2][4] Capital Market Trends - Capital markets are increasingly focused on upstream manufacturers, particularly the transition from hyaluronic acid to active materials such as recombinant collagen and PDRN. This shift is driven by rising consumer demand for facial treatments [7] - The market for light medical aesthetics accounts for approximately 70% in leading hospitals, with new medical aesthetics primarily divided into photonic and injection categories [8] Product Market Size - The market size for hyaluronic acid and botulinum toxin at the factory level is estimated to be between 50 to 100 billion yuan. The markup for mature products typically ranges from 2 to 3 times, with high-end products potentially reaching 3 to 4 times [9] - The regenerative materials market has seen rapid growth, with several companies achieving sales exceeding 1 billion yuan since 2021. However, these materials are not fully replacing hyaluronic acid but rather expanding the market [10][11] Material Development and Trends - The development of regenerative materials is significant, with a focus on micro-spheres that stimulate natural repair and collagen regeneration. These materials are expected to enhance treatment effectiveness and safety in soft tissue filling and skin management [15][16] - The future of the medical aesthetics industry is expected to shift towards active micro-spheres and humanized collagen, with a focus on extracellular matrix and various collagen types [15] Cosmetics Industry Overview - The cosmetics industry has seen a clear trend towards domestic brand replacement, with domestic brands now accounting for over 50% of the market. Brands are leveraging e-commerce and live streaming to enhance growth, with increased R&D investments focusing on efficacy and ingredient-driven strategies [2][21] - The market has shifted from high-end luxury products to a broader consumer base, with skincare products maintaining steady growth despite the pandemic [21][22] Sales Dynamics - The sales of domestic cosmetics exhibit seasonal variations, with the first half of the year accounting for about 40% of total sales and the second half for 60%. Major shopping events like 618 and Double Eleven significantly impact annual sales [24] R&D Investment Differences - There is a notable difference in R&D investment between the medical aesthetics and cosmetics industries. The medical aesthetics sector focuses on material iteration, while the cosmetics industry emphasizes brand building and marketing to enhance consumer loyalty [25] Future Outlook - The future of domestic cosmetics companies appears optimistic, with expectations of revenue growth driven by channel changes and ingredient innovations. Companies like Perfect Diary and Proya are projected to reach revenue levels of 20 to 30 billion yuan in the next 3 to 5 years [30]

Summary of the Conference Call for Xinyang Industry Overview - The medical aesthetics industry is characterized by a single-store profit margin of approximately 10% for mature institutions. Xinyang focuses on the anti-aging sector, reducing service product units (SPU), and targeting middle-class consumers with an average spending of over 2,000 yuan to meet annual anti-aging needs [2][4]. Key Points and Arguments - **Profitability Enhancement**: Xinyang aims to improve profitability through economies of scale and reduced customer acquisition costs. The user referral rate is increasing, which helps maintain low acquisition costs. Mature stores in first-tier cities have profit margins of about 10% to 15%, while stores in the ramp-up phase achieve around 10% net profit margin [2][6]. - **Supply Chain Strategy**: The company plans to increase its self-supply ratio from the current 15% to 30%-40% within the next three to four years, significantly lowering material costs. This is part of a broader strategy to enhance profit margins by controlling supply chain costs [7][8]. - **Store Expansion Plans**: Xinyang plans to open 50 stores by the end of 2025, primarily in first- and second-tier cities, with a focus on direct management and exploring a fully managed franchise model. By 2026, the company expects to open at least 30 more stores, bringing the total to over 80 [4][19]. - **Cost Structure**: In mature medical aesthetic institutions in first-tier cities, material costs account for about 45% of revenue, while labor costs (including doctors, nurses, and managers) range from 25% to 27%. Marketing costs stabilize around 10% after a year of operation [3][10]. - **Market Positioning**: Xinyang targets middle-class consumers with annual spending on aesthetic treatments between 10,000 to 20,000 yuan. The company aims to encourage 4 to 6 treatments per year to cover annual anti-aging needs [5][24]. - **Customer Retention and Product Strategy**: The company focuses on educating users about domestic products that offer similar quality at lower prices. This strategy is expected to help retain existing customers and attract new ones [12][24]. - **Profit Margin Goals**: Xinyang is confident in achieving a net profit margin of 20% in the long term, especially after increasing the self-supply ratio [24]. Additional Important Insights - **Challenges in Expansion**: The medical aesthetics industry faces challenges such as regional differences and reliance on high-quality store managers. Xinyang is addressing this through digital management to reduce dependence on high-salary managers [16][17]. - **Competitive Landscape**: The company believes its model is difficult to replicate due to its comprehensive system and established brand presence, which creates a flywheel effect for customer acquisition [18]. - **Performance in Second-Tier Cities**: Xinyang is testing its operational model in second-tier cities, with plans to open new stores and validate its approach based on experiences from first-tier cities [15][22]. - **Customer Spending Trends**: There has been a 20% increase in average spending per visit from existing customers in 2025, indicating a positive trend in customer engagement [23]. - **Future Strategic Focus**: The company will continue to prioritize offline chain operations, recognizing that the medical aesthetics sector requires a slower expansion pace compared to other industries like fast food [26]. This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Xinyang's focus on profitability, supply chain management, and market positioning within the medical aesthetics industry.